EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 95 filers reported holding EDGEWISE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $197,624 | -39.4% | 10,973 | -38.6% | 0.03% | -31.7% |
| Q1 2024 | $326,149 | +306.3% | 17,881 | +143.7% | 0.04% | +156.2% |
| Q4 2023 | $80,278 | +757.4% | 7,338 | +349.1% | 0.02% | +433.3% |
| Q3 2023 | $9,363 | +45.7% | 1,634 | +97.1% | 0.00% | +50.0% |
| Q2 2023 | $6,425 | +12.4% | 829 | -3.3% | 0.00% | 0.0% |
| Q1 2023 | $5,716 | -0.4% | 857 | +33.5% | 0.00% | 0.0% |
| Q4 2022 | $5,739 | +14.8% | 642 | +37.5% | 0.00% | 0.0% |
| Q3 2022 | $5,000 | – | 467 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |